Last reviewed · How we verify
Camrelizumab combined GP chemotherapy
Camrelizumab combined GP chemotherapy is a PD-1 inhibitor Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Nasopharyngeal carcinoma (in combination with gemcitabine-cisplatin chemotherapy), Esophageal squamous cell carcinoma (in combination with chemotherapy). Also known as: Camrelizumab, cisplatin and gemcitabine.
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, combined with gemcitabine and cisplatin chemotherapy for enhanced cytotoxic effect.
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, combined with gemcitabine and cisplatin chemotherapy for enhanced cytotoxic effect. Used for Nasopharyngeal carcinoma (in combination with gemcitabine-cisplatin chemotherapy), Esophageal squamous cell carcinoma (in combination with chemotherapy).
At a glance
| Generic name | Camrelizumab combined GP chemotherapy |
|---|---|
| Also known as | Camrelizumab, cisplatin and gemcitabine |
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and reversing immune exhaustion. When combined with gemcitabine-cisplatin (GP) chemotherapy, the immunotherapy synergizes with chemotherapy-induced tumor cell death and antigen release to amplify anti-tumor immunity.
Approved indications
- Nasopharyngeal carcinoma (in combination with gemcitabine-cisplatin chemotherapy)
- Esophageal squamous cell carcinoma (in combination with chemotherapy)
Common side effects
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Chemotherapy-related myelosuppression
- Nausea and vomiting
- Fatigue
Key clinical trials
- Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma (PHASE3)
- Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial (PHASE3)
- Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy (PHASE3)
- A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camrelizumab combined GP chemotherapy CI brief — competitive landscape report
- Camrelizumab combined GP chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Camrelizumab combined GP chemotherapy
What is Camrelizumab combined GP chemotherapy?
How does Camrelizumab combined GP chemotherapy work?
What is Camrelizumab combined GP chemotherapy used for?
Who makes Camrelizumab combined GP chemotherapy?
Is Camrelizumab combined GP chemotherapy also known as anything else?
What drug class is Camrelizumab combined GP chemotherapy in?
What development phase is Camrelizumab combined GP chemotherapy in?
What are the side effects of Camrelizumab combined GP chemotherapy?
What does Camrelizumab combined GP chemotherapy target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Nasopharyngeal carcinoma (in combination with gemcitabine-cisplatin chemotherapy)
- Indication: Drugs for Esophageal squamous cell carcinoma (in combination with chemotherapy)
- Also known as: Camrelizumab, cisplatin and gemcitabine